A Phase 1 interventional study of Docetaxel and Nintedanib in Carcinoma, Non-Small-Cell Lung, sponsored by Boehringer Ingelheim. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-29.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 20 under way, 3 of them phase 3. Docetaxel · Carcinoma, Non-Small-Cell Lung.
Among the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, this one is the 158th largest by enrollment of the 188 interventional ones that give a count, is one of 3 that started in 2016, is one of 20 in phase 1, and was the 164th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →13 of the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung are open now, in 8 countries. Recruiting first, the newest first:
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18+
Second Xiangya Hospital of Central South University · Sites in China
Ages 18–75
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
CatalYm GmbH · Sites in United States, Germany, Italy and 4 more countries
Ages 18+
Akeso · Sites in China
Ages 18–75
By country, each count listing its studies:
Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 143 · Phase 3 32 · Phase 4 2
First in 1996; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 50 across the 188 interventional studies. Of the 147 that completed or were terminated, 51 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 198 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim: 3 open now, 5 under way, 1 of them phase 3. Of 60 finished, 53 (88%) have results posted.
Among the 68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim, this one is the 40th largest by enrollment of the 49 interventional ones that give a count, is one of 7 that started in 2016, is one of 21 in phase 1, and was the 47th registered.
Boehringer Ingelheim’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 1999.
7 of the studies testing docetaxel in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06382129Phase 3Sichuan Baili Pharmaceutical Co., Ltd.A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02) | 2026-12 |
| NCT06928389Phase 3AkesoIvonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer | 2027-05 |
| NCT02889666Shanghai Jiao Tong University School of MedicineA Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer | 2026-12 |
| NCT07330050Tianjin Medical University Cancer Institute and HospitalWAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC | 2026-12-31 |
| NCT06879717iOncturaA Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients | 2027-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 68 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
Phase I study. To determine the MTD (Maximum Tolerated Dose) of nintedanib + weekly Docetaxel in patients with locally advanced or metastatic lung adenocarcinoma after failure of platinum-based first line chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-Patients with histologically/ confirmed locally advanced (Stage IIIB) or (Stage IV) lung adeno carcinoma after failure of platinum - based chemotherapy (patients with non-target lesion only are eligible).
First line chemotherapy may include continuation or switch maintenance therapy. One prior and/or neoadjuvant chemotherapy line is accepted. Prior immunotherapy is allowed.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nintedanib low dose with docetaxel
Drug: Docetaxel · Drug: Nintedanib
Nintedanib medium dose with docetaxel
Drug: Docetaxel · Drug: Nintedanib
Nintedanib high dose with docetaxel
Drug: Docetaxel · Drug: Nintedanib
Nintedanib continuous high dose with docetaxel
Drug: Docetaxel · Drug: Nintedanib
Low Dose
Medium dose
High dose
Continuous high dose
Maximum Tolerated Dose (MTD) of Nintedanib Administered in Combination With Docetaxel
Maximum tolerated dose (MTD) of nintedanib administered in combination with docetaxel. The MTD was defined as the highest dose combination studied for which the incidence of DLTs was no more than 1 out of 6 subjects experiencing a DLT during the first treatment cycle i.e. the incidence of DLTs was no more than 17%. In case dose escalation reached dose level 3 (200 mg bid nintedanib administered without interruption on days of docetaxel infusion) and no more than 1 out of 6 subjects experienced a DLT during the first 28-day cycle at this dose level, dose level 3 was considered the MTD.
Time frame: First treatment cycle, the first 28 days following the start of trial medication.
Number of Participants With Dose-limiting Toxicity (DLT) During the First Treatment Cycle
Number of participants with DLT occurring during the first treatment cycle. DLT was defined as any of the following adverse events related to nintedanib: * Non-haematological drug-related Common Terminology Criteria for AEs (CTCAE) grade 3 or greater * diarrhoea CTCAE grade 2 for \>7 days despite supportive care * nausea CTCAE grade 3 or greater despite supportive care * vomiting CTCAE grade 2 or greater despite supportive care * increase in Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) to CTCAE grade 3 or greater * A increase in ALT and/or AST to CTCAE grade 2 or greater in conjunction with * total bilirubin increase of CTCAE grade 1 or greater * Platelets \<50 000/mm3 with bleeding (CTCAE ≥3) * neutropenia of any grade or duration accompanied by fever \>38.5°C * neutropenia grade 4 without fever of \>7 days duration * Inability to resume nintedanib dosing within 21 days after stopping due to toxicity.
Time frame: First treatment cycle, the first 28 days following the start of trial medication.
This study is an open-label Phase I of oral nintedanib plus weekly docetaxel therapy in subjects with locally advanced or metastatic lung adenocarcinoma after failure of platinum-based first-line chemotherapy.
| Milestone | 150 mg Nintedanib + Docetaxel | 200 mg Nintedanib + Docetaxel |
|---|---|---|
| Started | 7 | 7 |
| Completed | 0 | 1 |
| Not completed | 7 | 6 |
| Withdrew: Progressive disease | 6 | 3 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Withdrawal from the trial | 0 | 1 |
| Withdrew: Lack of benefit and side effects | 1 | 0 |
Maximum tolerated dose (MTD) of nintedanib administered in combination with docetaxel. The MTD was defined as the highest dose combination studied for which the incidence of DLTs was no more than 1 out of 6 subjects experiencing a DLT during the first treatment cycle i.e. the incidence of DLTs was no more than 17%. In case dose escalation reached dose level 3 (200 mg bid nintedanib administered without interruption on days of docetaxel infusion) and no more than 1 out of 6 subjects experienced a DLT during the first 28-day cycle at this dose level, dose level 3 was considered the MTD.
| milligram | Nintedanib + Docetaxel |
|---|---|
| Maximum Tolerated Dose (MTD) of Nintedanib Administered in Combination With Docetaxel | NA |
Number of participants with DLT occurring during the first treatment cycle. DLT was defined as any of the following adverse events related to nintedanib: * Non-haematological drug-related Common Terminology Criteria for AEs (CTCAE) grade 3 or greater * diarrhoea CTCAE grade 2 for \>7 days despite supportive care * nausea CTCAE grade 3 or greater despite supportive care * vomiting CTCAE grade 2 or greater despite supportive care * increase in Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) to CTCAE grade 3 or greater * A increase in ALT and/or AST to CTCAE grade 2 or greater in conjunction with * total bilirubin increase of CTCAE grade 1 or greater * Platelets \<50 000/mm3 with bleeding (CTCAE ≥3) * neutropenia of any grade or duration accompanied by fever \>38.5°C * neutropenia grade 4 without fever of \>7 days duration * Inability to resume nintedanib dosing within 21 days after stopping due to toxicity.
| Participants | 150 mg Nintedanib + Docetaxel | 200 mg Nintedanib + Docetaxel |
|---|---|---|
| Number of Participants With Dose-limiting Toxicity (DLT) During the First Treatment Cycle | 1 | 1 |
Collected over From first administration of study drug till the last administration + a residual effect period (REP) of 28 days, up to 330 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 150 mg Nintedanib + Docetaxel | 0/7 (0%) | 3/7 (42.9%) | 6/7 (85.7%) |
| 200 mg Nintedanib + Docetaxel | 0/7 (0%) | 2/7 (28.6%) | 6/7 (85.7%) |
| Event | 150 mg Nintedanib + Docetaxel | 200 mg Nintedanib + Docetaxel |
|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/7 | 0/7 |
| NauseaGastrointestinal disorders | 1/7 | 0/7 |
| General physical health deteriorationGeneral disorders | 0/7 | 1/7 |
| EmpyemaInfections and infestations | 0/7 | 1/7 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/7 | 1/7 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/7 | 0/7 |
| Event | 150 mg Nintedanib + Docetaxel | 200 mg Nintedanib + Docetaxel |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 5/7 | 4/7 |
| AnaemiaBlood and lymphatic system disorders | 3/7 | 1/7 |
| NauseaGastrointestinal disorders | 2/7 | 3/7 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/7 | 0/7 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 3/7 | 1/7 |
| ConstipationGastrointestinal disorders | 2/7 | 0/7 |
| VomitingGastrointestinal disorders | 0/7 | 2/7 |
| AstheniaGeneral disorders | 2/7 | 0/7 |
| FatigueGeneral disorders | 2/7 | 2/7 |
| Mucosal inflammationGeneral disorders | 2/7 | 0/7 |
Treated set (TS): all subjects who received at least one dose of study medication. The TS was used for all safety and efficacy analyses
| Age, Continuous(years) | 150 mg Nintedanib + Docetaxel | 200 mg Nintedanib + Docetaxel | Total |
|---|---|---|---|
| Mean | 67.0 ± 7.6 | 60.3 ± 7.8 | 63.6 ± 8.2 |
| Sex: Female, Male(Participants) | 150 mg Nintedanib + Docetaxel | 200 mg Nintedanib + Docetaxel | Total |
|---|---|---|---|
| Female | 2 | 2 | 4 |
| Male | 5 | 5 | 10 |
| Race/Ethnicity, Customized(Participants) | 150 mg Nintedanib + Docetaxel | 200 mg Nintedanib + Docetaxel | Total |
|---|---|---|---|
| White | 5 | 5 | 10 |
| Not reported due to local law restrictions | 2 | 2 | 4 |
| Race/Ethnicity, Customized(Participants) | 150 mg Nintedanib + Docetaxel | 200 mg Nintedanib + Docetaxel | Total |
|---|---|---|---|
| Not Hispanic or Latino | 5 | 5 | 10 |
| Not reported due to local law restrictions | 2 | 2 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2016 to primary completion in Nov 2019, 44 months.
Results were first posted in Jan 2021, 1 year 2 months after primary completion.
Of 473 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 44 months is below that.
Counting every sponsor, half of 699 studies reached it within 50 months; a quarter within 31 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Docetaxel · Nintedanib
Carcinoma, Non-Small-Cell Lung →